The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review
Open accessThe DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index; 68 of the 113 sources its claims cite were checked for support.
Abstract
Introduction: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive and invasive malignancies, with limited response to the currently available systemic therapy options. Having a 5-year survival of 12%, there is a serious need for novel therapeutic options, including drug repurposing for the treatment of PDAC. In recent years, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) inhibitors, also known as statins, have been identified as potential candidates for PDAC therapy repurposing. Methods: We have performed a scoping literature review to summarize the extent of knowledge on statins' effects on PDAC, both in clinical studies and preclinical models, and to explain the mechanisms underlying statins' antiproliferative effect on PDAC. We have followed the PRISMA Extension for Scoping Reviews (PRISMA-ScR) guidelines. We have searched PubMed and Web of Science for original articles published between January 2021 and January 2026. Results: Our review systematically linked the clinical outcomes, molecular mechanism, and tumor microenvironment in PDAC-statin research. Clinical studies of the correlation between statin treatment and PDAC incidence yielded mixed results. Among the mechanisms we have summarized are disruption of the plasma membrane lipid rafts, reduction of protein prenylation, increase of the tumor immunogenicity, reduction of signaling, both RAS-mediated and by alternative pathways, and disruption of mitochondrial respiration. Statins also showed synergistic effects with chemotherapeutic agents including gemcitabine, 5-fluorouracil, and oxaliplatin in preclinical models. Discussion: Despite promising preclinical data, the clinical evidence remains limited to observational studies and a single phase 2 trial. Randomized controlled trials with biomarker-driven patient selection are needed to establish the role of statins as adjuvant therapy in PDAC.
Overview
CoChat Summary
TL;DR
This scoping review maps 2021–2026 evidence on statins in pancreatic ductal adenocarcinoma (PDAC), linking mixed clinical outcomes with convergent preclinical mechanisms. It concludes that preclinical antitumor signals are promising, but clinical evidence remains preliminary and insufficient to support statins as antitumor therapy in PDAC.
Key findings
- Clinical evidence is mixed: PDAC incidence studies reported increased risk with >5 years statin use (HR 1.77, 95% CI 1.16–2.70, p = 0.04), no impact (HR 0.98, 95% CI 0.61–1.60), and reduced incidence in an ILD/pulmonary fibrosis cohort (adjusted HR 0.42, 95% CI 0.29–0.63).
- Survival studies showed mostly positive but non-uniform signals: post-diagnosis statin use was associated with improved OS (e.g., HR 0.86, 95% CI 0.76–0.97; duration categories with p-trend = 0.04), while preoperative statin use in one multicentric cohort showed no significant OS or DFS benefit.
- The only reported clinical trial, single-arm phase 2 NCT06241352, enrolled 42 locally advanced/metastatic PDAC patients receiving atorvastatin 80 mg/day with chemotherapy; ≥20% CA19-9 reduction occurred in 70.3%, with median PFS 8.05 months.
- Preclinical studies identified multiple mechanisms: mevalonate pathway inhibition, reduced KRAS prenylation, lipid raft disruption, YAP/TAZ downregulation, PD-L1 reduction, immune microenvironment remodeling, mitochondrial dysfunction, and synergy with gemcitabine, 5-fluorouracil, and oxaliplatin.
Methods
- Scoping review following PRISMA-ScR, with a prewritten protocol and PCC framework; PubMed and Web of Science were searched for original articles published from January 2021 to January 2026.
- Inclusion criteria covered PDAC patients, cancer-free subjects, or human PDAC preclinical models treated with statins; exclusions included reviews, meta-analyses, conference abstracts, non-PDAC, non-human models, no statin intervention, older articles, and non-English articles.
- From 135 records, 16 duplicates were removed, 67 records were removed at title/abstract screening, 4 full texts were unavailable, 20 full texts were excluded, and 28 reports were included; data were charted independently by two reviewers and synthesized narratively.
Limitations
- The paper states that limiting the search to the past 5 years risks excluding older relevant studies, and that only PubMed and Web of Science were searched.
- The paper states that data heterogeneity prevented meta-analysis, the scoping review design did not include formal quality assessment of individual studies, and clinical evidence is predominantly observational while many preclinical studies used supraphysiological statin concentrations.
- Evident from the text: the clinical evidence includes contradictory observational findings and only one single-arm phase 2 trial, with no randomized controlled trial data; the review also notes no study has quantified intratumoral statin concentrations in PDAC.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
64 Valid · 1 Not valid · 42 Not checked · 44 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Interestingly, the only KRAS mutant lines without a statistically significant better response to simvastatin were those that also had BRAF mutations.”
§ The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review > Results > Preclinical data in PDAC models
What the sources say
- Supportedcites Nam et al., 2021 source
The Results section (“KRAS mutation renders tumors susceptible to statin”; page not supplied) reports a significant response in KRAS-mutant cells compared with KRAS-wild-type cells. It identifies two nonresponding KRAS-mutant models—139T patient-derived cells and the LS174T cell line—and states that both also carried BRAF mutations. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The simvastatin + oxaliplatin group also had infiltrates with more CD8+ T-cells than the other groups (Nam et al., 2021).”
§ The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review > Results > Preclinical data in PDAC models
What the sources say
- Supportedcites Nam et al., 2021 source
The Results section reports that CD8+ T-cell infiltration into tumors was robustly increased in the simvastatin-plus-oxaliplatin groups (figure 5L). It also reports increased numbers of CD8+ T cells in the tumor microenvironment after combination therapy (figure 5G). (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A convergent mechanism identified across multiple studies is the disruption of plasma membrane lipid rafts by statins through intracellular cholesterol depletion (Duranti et al., 2025; Gyoten et al., 2023).”
§ The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review > Results > Preclinical data in PDAC models
What the sources say
- Partly supportedcites Duranti et al., 2025 sourceExperimental — accuracy not yet measured
The Results section (“Lowering cellular cholesterol content with statins…,” page unavailable) reports that simvastatin reduced free cholesterol and reduced the hERG1/β1 integrin complex’s colocalization with the raft-associated protein caveolin-1. This supports cholesterol depletion and altered raft-associated signaling in the cells studied, but the paper does not directly establish disruption of plasma membrane lipid rafts as a general statin mechanism. (LLM, conf=0.82)
- Supportedcites Gyoten et al., 2023 source
The Results (§2.3; page not provided) report that lovastatin reduced both membrane cholesterol and plasma-membrane rafts in pancreatic cancer cells. The Introduction (§1) states that statins lower intracellular cholesterol, and the Discussion (§3) links their HMG-CoA reductase inhibition to effects on plasma-membrane rafts. The ‘across multiple studies’ framing belongs to the citing sentence, not to this source alone. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“the HMGCR expression is negatively correlated with PDAC sensitivity to 5-fluorouracil (5-FU)”
§ The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review > Results > Preclinical data in PDAC models
What the sources say
- Supportedcites Xing et al., 2024 source
In the Results section (‘Abnormal activation of the mevalonate pathway promotes 5-FU resistance in PC’), HMGCR levels were markedly higher in the 5-FU-resistant group than in the 5-FU-sensitive group. The authors conclude that elevated HMGCR is linked to reduced 5-FU efficacy in the pancreatic cancer patients studied, who received a 5-FU-containing FOLFIRINOX regimen. (LLM, conf=0.89)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Nam et al. reported greater sensitivity in KRAS-mutant compared with wild-type cancers”
§ The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review > Discussion > Potential biomarkers for statin response in PDAC
What the sources say
- Supportedcites Nam et al., 2021 source
In Results (‘KRAS mutation renders tumors susceptible to statin’), simvastatin reduced proliferation and increased apoptosis in KRAS-mutant cancer cells compared with KRAS-wild-type cells. The same section reports greater loss of viability in KRAS-mutant patient-derived cancer cells, while noting an exception for cells with both KRAS and BRAF mutations. Page numbers are not provided in our copy. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 41 with their cited sources checked
Create a free account to see all 151 claims and to verify the 2 references still open.
- Probably not a substantial claim. 17
- It may state two separate claims as one. 45
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review > Results > Preclinical data in PDAC models
“In a combination study with anti-inflammatory medicine, it was demonstrated that combination treatment with simvastatin, celecoxib, and tipifarnib decreases the PANC-1 cells ability to form spheres (Xu et al., 2021).”
§ The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review > References
“47. Xu X.-T. Chen J. Xiang R. Ma Y. R. Wang X. Ma Y. Y. (2021). Effects of atorvastatin in combination with celecoxib and tipifarnib on proliferation and apoptosis in pancreatic cancer sphere-forming cells.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review > Results > Clinical studies assessing statin use in PDAC patients
“Similar results have been obtained in an observational cohort analysis using real-world evidence in a Hong Kong cohort (Xu et al., 2024) of 118,914 individuals who started statin treatment between 2009 and 2011 and were matched to non-statin using subjects. This study didn’t report any impact of statin use on PDAC incidence (HR 0.98, 95% CI 0.61–1.60).”
§ The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review > Results > Clinical studies assessing statin use in PDAC patients
“The PDAC incidence rate in the >5 years of use was significantly higher with a hazard ratio (HR) of 1.77, and 95% confidence interval (CI) of 1.16–2.70, p = 0.04, which would indicate the long-term statin use as a PDAC development risk factor.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review > Results > Clinical studies assessing statin use in PDAC patients
“Uemura et al. compared the OS and RFS outcomes of 47 resected PDAC patients with perioperative statin use with those of never-treated with statins resected PDAC patients, reporting statistically significant differences, favoring the statin intake group (Uemura et al., 2023).”
§ The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review > Results > Clinical studies assessing statin use in PDAC patients
“| Uemura et al. (2023) | Retrospective surgical cohort | Japan | 47 resectedPDAC patients | OS, RFS |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review > Results > Clinical studies assessing statin use in PDAC patients
“In resectable disease, the evidence consistently reveals that perioperative statin use was associated with improved overall survival.”
§ The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review > Results > Clinical studies assessing statin use in PDAC patients
“No statistically significant differences in OS and DFS between the patients treated with statins and those never treated with statins were reported (Joliat et al., 2023).”
Citations
Cites
PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation
Tricco, A. C., Lillie, E., Zarin, W., O'Brien, K. K., Colquhoun, H., Levac, D., Moher, D., Peters, M. D. J., Horsley, T., Weeks, L., et al. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0850 · Cited by 43,565 · cited 1×
“This scoping review was conducted in accordance with the PRISMA Extension for Scoping Reviews (PRISMA-ScR) (Tricco et al., 2018).”
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810 · cited 1×
“In the advanced/metastatic disease, the median OS of the patients treated with mFOLFIRINOX is 11.1 months (Conroy et al., 2011), while the patients treated with other systemic therapy regimens, such as gemcitabine + nab-paclitaxel have a median OS of 8.5 months according to the MPACT trial (Hoff et…”
InfluentialRahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094 · cited 1×
“PDAC is estimated to become the second-highest mortality cancer in several Western countries within the next decade, emphasizing the necessity for novel therapeutic approaches (Rahib et al., 2014).”
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302 · cited 1×
“In the subgroup of BRCA-mutated PDAC, which accounts for roughly 5%–7% of patients, olaparib has already shown benefit as maintenance treatment after platinum-based chemotherapy (Golan et al., 2019).”
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 1×
“Approximately 90% of PDAC cases harbor a Kirsten rat sarcoma (KRAS) mutation (Prior et al., 2012).”
Mevalonate pathway: A review of clinical and therapeutical implications
Buhaescu, I., & Izzedine, H. (2007) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2007.03.016 · Cited by 620 · cited 2×
“The mevalonate pathway is centrally regulated at the transcriptional level by sterol regulatory element-binding proteins (SREBPs) (Buhaescu and Izzedine, 2007).”
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
Hallin, J., Bowcut, V., Calinisan, A., Briere, D. M., Hargis, L., Engstrom, L. D., Laguer, J., Medwid, J., Vanderpool, D., Lifset, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02007-7 · Cited by 553
Wainberg, Z. A., Melisi, D., Macarulla, T., Pazo Cid, R., Chandana, S. R., De La Fouchardière, C., Dean, A., Kiss, I., Lee, W. J., Goetze, T. O., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01366-1 · Cited by 516 · cited 1×
“A newer regimen, NALIRIFOX (a chemotherapy triplet of 5-fluorouracil, liposomal irinotecan, and oxaliplatin) yielded similar results: a median OS of 11.1 months in the NAPOLI-3 trial (Wainberg et al., 2023).”
InfluentialGuillaumond, F., Bidaut, G., Ouaissi, M., Servais, S., Gouirand, V., Olivares, O., Lac, S., Borge, L., Roques, J., Gayet, O., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421601112 · Cited by 454 · cited 1×
“The PDAC cells’ reliance on lipid (especially cholesterol metabolism) is among the many resistance mechanisms of the PDAC (Guillaumond et al., 2015), thus it has been hypothesized that cholesterol-lowering drugs such as 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) inhibitors (statins)…”
KRAS mutation in pancreatic cancer
Luo, J. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.02.003 · Cited by 360 · cited 1×
“The development of KRAS G12C inhibitors such as sotorasib and adagrasib marked a meaningful advance in precision oncology, but their relevance in pancreatic ductal adenocarcinoma remains limited because KRAS G12C is present in only about 1%–2% of PDAC cases (Luo, 2021).”
Conroy, T., Castan, F., Lopez, A., Turpin, A., Ben Abdelghani, M., Wei, A. C., Mitry, E., Biagi, J. J., Evesque, L., Artru, P., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.3829 · Cited by 344 · cited 1×
“…the combination of gemcitabine and capecitabine, the former having yielded a median overall survival (OS) of 53.5 months in the PRODIGE 24 trial (Conroy et al., 2022), with a 5-year survival of 43.2%, while the latter a median OS of 29.5 months according to the ESPAC-4 trial (Palmer et al.,…”
InfluentialLuchini, C., Brosens, L. A. A., Wood, L. D., Chatterjee, D., Shin, J. I., Sciammarella, C., Fiadone, G., Malleo, G., Salvia, R., Kryklyva, V., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-320726 · Cited by 258 · cited 1×
“By contrast, immune checkpoint blockade has produced little benefit in PDAC overall, with meaningful responses largely restricted to the microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) patients, who represent 1%–2% of PDAC cases (Luchini et al., 2021; Marabelle et al., 2025).”
What is a relevant statin concentration in cell experiments claiming pleiotropic effects?
Björkhem‐Bergman, L., Lindh, J. D., & Bergman, P. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03907.x · Cited by 207 · cited 1×
“In vitro work commonly uses statin concentrations between 1 and 50 μM, whereas standard clinical dosing usually produces peak plasma levels in the 10–100 nM range for most statins (Björkhem-Bergman et al., 2011).”
Statins as Anticancer Agents in the Era of Precision Medicine
Longo, J., van Leeuwen, J. E., Elbaz, M., Branchard, E., & Penn, L. Z. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1967 · Cited by 196 · cited 1×
“The mevalonate pathway byproducts, farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), determine the KRAS protein prenylation which in turn determines the KRAS anchoring to the cell membrane, facilitating the KRAS-mediated cell signaling (Longo et al., 2020).”
Truong, L.-H., & Pauklin, S. (2021) · Cancers · doi:10.3390/cancers13195028 · Cited by 102
Targeting the Mevalonate Pathway Inhibits the Function of the Epidermal Growth Factor Receptor
Mantha, A. J., Hanson, J. E. L., Goss, G., Lagarde, A. E., Lorimer, I. A., & Dimitroulakos, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1951 · Cited by 101 · cited 1×
“Moreover, inhibition of the mevalonate pathway exerts a strong impact on several oncogenic signaling pathways (Mantha et al., 2005).”
Nam, G.-H., Kwon, M., Jung, H., Ko, E., Kim, S. A., Choi, Y., Song, S. J., Kim, S., Lee, Y., Kim, G. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002474 · Cited by 82 · cited 4×
“Nam et al. demonstrated that simvastatin has a better antiproliferative effect in KRAS mutant cancers compared with KRAS wild-type by comparing the effect of simvastatin on multiple murine and human colorectal cancer cell lines with different mutational profiles (Nam et al., 2021).”
InfluentialMarabelle, A., O’Malley, D. M., Hendifar, A. E., Ascierto, P. A., Motola‐Kuba, D., Penel, N., Cassier, P. A., Bariani, G. M., Jesus‐Acosta, A. D., Doi, T., et al. (2025) · Nature Cancer · doi:10.1038/s43018-024-00894-y · Cited by 61 · cited 1×
“By contrast, immune checkpoint blockade has produced little benefit in PDAC overall, with meaningful responses largely restricted to the microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) patients, who represent 1%–2% of PDAC cases (Luchini et al., 2021; Marabelle et al., 2025).”
Dorsch, M., Kowalczyk, M., Planque, M., Heilmann, G., Urban, S., Dujardin, P., Forster, J., Ueffing, K., Nothdurft, S., Oeck, S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110056 · Cited by 55 · cited 1×
“Fluvastatin promoted EMT and reduced the ability of PDAC cells to organize themselves in spheric tridimensional structures (Dorsch et al., 2021).”
Statin use improves survival in patients with pancreatic ductal adenocarcinoma: A meta-analysis
Tamburrino, D., Crippa, S., Partelli, S., Archibugi, L., Arcidiacono, P. G., Falconi, M., & Capurso, G. (2020) · Digestive and Liver Disease · doi:10.1016/j.dld.2020.01.008 · Cited by 54 · cited 5×
“While statins are well-established inhibitors of the mevalonate pathway, which is critical for cholesterol biosynthesis and the production of inflammatory mediators, their broader impact on cellular processes relevant to cancer biology remains incompletely understood (Tamburrino et al., 2020).”
InfluentialLi, Y., Tang, S., Wang, H., Zhu, H., Lu, Y., Zhang, Y., Guo, S., He, J., Li, Y., Zhang, Y., et al. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.07.008 · Cited by 53 · cited 7×
“NCT06241352 (Li et al., 2025) is, to the best of our knowledge, the only clinical trial with reported results involving statins administration in PDAC patients to assess statins’ antitumoral effects.”
InfluentialPancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial
Palmer, D. H., Jackson, R., Springfeld, C., Ghaneh, P., Rawcliffe, C. L., Halloran, C. M., Faluyi, O. O., Cunningham, D., Wadsley, J., Darby, S., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.01118 · Cited by 52 · cited 1×
“…and capecitabine, the former having yielded a median overall survival (OS) of 53.5 months in the PRODIGE 24 trial (Conroy et al., 2022), with a 5-year survival of 43.2%, while the latter a median OS of 29.5 months according to the ESPAC-4 trial (Palmer et al., 2025), with a 5-year survival of 32%.”
InfluentialShinkawa, T., Ohuchida, K., Mochida, Y., Sakihama, K., Iwamoto, C., Abe, T., Ideno, N., Mizuuchi, Y., Shindo, K., Ikenaga, N., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02301-9 · Cited by 41 · cited 3×
“In another study (Shinkawa et al., 2022) with the aim to assess PDAC dependency on niche factors for differentiation, a co-culture of PDAC PDOs and CAFs was generated.”
InfluentialGyoten, M., Luo, Y., Fujiwara-Tani, R., Mori, S., Ogata, R., Kishi, S., & Kuniyasu, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316814 · Cited by 28 · cited 4×
“A convergent mechanism identified across multiple studies is the disruption of plasma membrane lipid rafts by statins through intracellular cholesterol depletion (Duranti et al., 2025; Gyoten et al., 2023).”
InfluentialChen, Y., Huang, Y., Yang, S., Yen, H., Tsai, H., Hsieh, M., & Hsiao, Y. (2021) · Environmental Toxicology · doi:10.1002/tox.23146 · Cited by 26 · cited 1×
“Pitavastatin and metformin showed a synergistic cytotoxic effect on PANC-1 and AsPC-1 cell lines by determining G0 cell cycle arrest, upregulated cleaved poly (ADP-ribose) polymerase 1 (PARP-1), cleaved caspase-3, and inhibiting PI3K/mTOR (Chen et al., 2021).”
Xu, X.-T., Chen, J., Ren, X., et al. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173840 · Cited by 25 · cited 2×
“Pitavastatin and metformin showed a synergistic cytotoxic effect on PANC-1 and AsPC-1 cell lines by determining G0 cell cycle arrest, upregulated cleaved poly (ADP-ribose) polymerase 1 (PARP-1), cleaved caspase-3, and inhibiting PI3K/mTOR (Chen et al., 2021).”
Minz, A. P., Mohapatra, D., Dutta, M., Sethi, M., Parida, D., Mohapatra, A. P., Mishra, S., Kar, S., Sasmal, P. K., & Senapati, S. (2023) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-023-03562-9 · Cited by 24 · cited 2×
“The weights of the tumors in the simvastatin + gemcitabine group were significantly lower than those in the other groups (Minz et al., 2023).”
Gu, X. Q., Zhu, Q., Tian, G., Song, W., Wang, T., Wang, A., Chen, X., & Qin, S. (2022) · Cancer Medicine · doi:10.1002/cam4.4683 · Cited by 24 · cited 2×
“Further, using PDAC cell xenografts implanted in mice, it was demonstrated that atorvastatin has efficiently suppressed PDAC KIF11-high tumor growth (Gu et al., 2022).”
Støer, N. C., Bouche, G., Pantziarka, P., Sloan, E. K., Andreassen, B. K., & Botteri, E. (2021) · Acta Oncologica · doi:10.1080/0284186x.2021.1953136 · Cited by 22 · cited 6×
“…incidence) in subjects not yet diagnosed with cancer, or OS, disease-free survival (DFS)/relapse-free survival (RFS) in cancer patients (including PDAC patients) (Guo et al., 2025; Joliat et al., 2023; Okita et al., 2024; Stoer et al., 2021; Uemura et al., 2023; Xu et al., 2024; Yeh et al., 2021).”
InfluentialYeh, J.-J., Lai, J.-N., Lin, C.-L., Hsu, C.-Y., & Kao, C.-H. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-047039 · Cited by 16 · cited 4×
“…incidence) in subjects not yet diagnosed with cancer, or OS, disease-free survival (DFS)/relapse-free survival (RFS) in cancer patients (including PDAC patients) (Guo et al., 2025; Joliat et al., 2023; Okita et al., 2024; Stoer et al., 2021; Uemura et al., 2023; Xu et al., 2024; Yeh et al., 2021).”
Influential(2023) · PubMed Central · Cited by 15
Long-term use of anti-cholesterol drugs and cancer risks in a Japanese population
Okita, Y., Sobue, T., Zha, L., Kitamura, T., Iwasaki, M., Inoue, M., Yamaji, T., Tsugane, S., & Sawada, N. (2024) · Scientific Reports · doi:10.1038/s41598-024-53252-4 · Cited by 14 · cited 4×
“…incidence) in subjects not yet diagnosed with cancer, or OS, disease-free survival (DFS)/relapse-free survival (RFS) in cancer patients (including PDAC patients) (Guo et al., 2025; Joliat et al., 2023; Okita et al., 2024; Stoer et al., 2021; Uemura et al., 2023; Xu et al., 2024; Yeh et al., 2021).”
InfluentialSimvastatin Attenuated Tumor Growth in Different Pancreatic Tumor Animal Models
Chen, C.-Y., Yang, Y.-F., Wang, P. C., Shan, L., Lin, S., Chen, P.-J., Chen, Y.-J., Chiang, H.-S., Lin, J.-T., Hung, C.-F., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15111408 · Cited by 13
The molecular basis of the anticancer effect of statins
Buccioli, G., Testa, C., Jacchetti, E., Pinoli, P., Carelli, S., Ceri, S., & Raimondi, M. T. (2024) · Scientific Reports · doi:10.1038/s41598-024-71240-6 · Cited by 13 · cited 1×
“Notably, the IC50 of statins for their primary target, HMGCR, is in the low nanomolar range (Buccioli et al., 2024), which is well within clinically achievable plasma concentrations.”
Zhang, D., Lu, P., Zhu, K., Wu, H., & Dai, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.724437 · Cited by 11
Teper, Y., Ye, L., Waldron, R. T., Lugea, A., Sun, X., Sinnett-Smith, J., Hines, O. J., Pandol, S. J., Rozengurt, E., & Eibl, G. (2023) · Scientific Reports · doi:10.1038/s41598-023-43498-9 · Cited by 10 · cited 2×
“These discoveries are supported by another study (Teper et al., 2023) of four-week-old obese KRASG12D mutant male mice that were treated with simvastatin in combination with metformin, which, compared to female mice or mice treated with either simvastatin or metformin, had a lower risk of PanIn-3.”
Ou, Y., Wang, R., Chu, G. C., Elmadbouh, O. H. M., Lim, A., Chung, L. W. K., Edderkaoui, M., Zhang, Y., & Pandol, S. J. (2022) · Advanced Therapeutics · doi:10.1002/adtp.202200021 · Cited by 10 · cited 3×
“It was demonstrated that the anticancer effect is due to the DZ-SIM accumulation in the mitochondria and the subsequent mitochondrial dysfunction (Ou et al., 2022).”
Long-term statin use and risk of cancers: a target trial emulation study
Xu, W., Chan, L. S., Danaei, G., Lu, Y., & Wan, E. Y. F. (2024) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2024.111425 · Cited by 8
Duranti, C., Iorio, J., Manganelli, V., Bagni, G., Colasurdo, R., Lottini, T., Martinelli, M., Capitani, C., Boso, G., D’Alessandro, F. N., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02321-2 · Cited by 8 · cited 4×
“A convergent mechanism identified across multiple studies is the disruption of plasma membrane lipid rafts by statins through intracellular cholesterol depletion (Duranti et al., 2025; Gyoten et al., 2023).”
InfluentialRimpelová, S., Kolář, M., Strnad, H., Ruml, T., Vítek, L., & Gbelcová, H. (2021) · Molecules · doi:10.3390/molecules26123528 · Cited by 8 · cited 3×
“…established that cerivastatin, pitavastatin, and simvastatin had the most significant transcriptomic impact on MIA PaCa-2 PDAC cell line, producing growth arrest and cytoskeletal remodeling, compared to lovastatin, fluvastatin, atorvastatin, pravastatin, and rosuvastatin (Rimpelová et al., 2021).”
Sun, J., Wang, J.-M., Zhang, Q., Lin, W.-Y., Tang, L., Lu, S.-Y., Li, B.-Q., Du, Z.-X., & Wang, H.-Q. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03561-x · Cited by 5 · cited 2×
“In that context, newer delivery platforms such as the DZ-SIM nanoconjugate (Ou et al., 2022) and hyaluronic acid-coated nanoparticles (Sun et al., 2025) are of particular interest, because they may help overcome these pharmacokinetic limitations.”
DESAI, V., TADINADA, S. M., SHAGHAGHI, H., SUMMER, R., LAI, J. C. K., & BHUSHAN, A. (2024) · Anticancer Research · doi:10.21873/anticanres.17038 · Cited by 5 · cited 1×
“Desai et al. demonstrated that the combination of atorvastatin and biochanin A synergistically decreased the viability of PDAC cells in PANC-1, AsPC-1, MIA PaCa-2 lines, the underlying mechanism being the inhibition of mitochondrial respiratory chain complexes (Desai et al., 2024).”
Miao, H., Zhang, B., Li, Y., Ma, X., Yang, Y., Lin, Z., & Liu, Y. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111753 · Cited by 5 · cited 1×
“On the other hand, however, Miao et al. showed that rosuvastatin inhibits EMT by calcium-mediated endoplasmic reticulum stress, thus diminishing PDAC cell metastatic capacity (Miao et al., 2025).”
Highly variable biological effects of statins on cancer, non-cancer, and stem cells in vitro
Gbelcová, H., Rimpelová, S., Jariabková, A., Macášek, P., Priščáková, P., Ruml, T., Šáchová, J., Kubovčiak, J., Kolář, M., & Vítek, L. (2024) · Scientific Reports · doi:10.1038/s41598-024-62615-w · Cited by 4 · cited 1×
“Statins, however, have disorganized the tridimensional spheroid structures (Gbelcová et al., 2024).”
Statin use after cancer diagnosis and survival among patients with cancer
Guo, H., Malone, K. E., Heckbert, S. R., & Li, C. I. (2025) · Cancer Causes & Control · doi:10.1007/s10552-024-01939-4 · Cited by 4 · cited 5×
“…on survival was analyzed on statin use duration categories: < 1 year, 1–2 years, 2–3 years, > 3 years, with higher benefits on OS in the 1–2 years category compared to 1 category, and respectively 2–3 years category compared to 1–2 years category, with a p trend value of 0.04 (Guo et al., 2025).”
InfluentialTargeting the mevalonate pathway enhances the efficacy of 5-fluorouracil by regulating pyroptosis
Xing, Z., Ma, Y., Jiang, X., Qing, H., Wu, Y., Che, S., Gao, Z., Wang, K., Wang, T., He, Q., et al. (2024) · Medical Oncology · doi:10.1007/s12032-024-02557-5 · Cited by 4 · cited 3×
“HMGCR expression may also be relevant, given the inverse association with 5-FU sensitivity (Xing et al., 2024).”
Ako, S., Teper, Y., Ye, L., Sinnett-Smith, J., Hines, O. J., Rozengurt, E., & Eibl, G. (2022) · Gastro Hep Advances · doi:10.1016/j.gastha.2022.04.012 · Cited by 3
Joliat, G.-R., Gaspar-Figueiredo, S., Labgaa, I., Vrochides, D., Perinel, J., Adham, M., Demartines, N., & Schäfer, M. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05426-2 · Cited by 3
Statins exert anti-growth effects by suppressing YAP/TAZ expressions via JNK signal activation and eliminate the immune suppression by downregulating PD-L1 expression in pancreatic cancer
Uemura (2023) · Am. J. CANCER Res.
Unresolved
Metadata
- Authors
- Pîntea, A.-I., Croitoru, A. E., Dinu-Pîrvu, C. E., & Dima, S. O.
- Affiliations
- Fundeni Clinical Institute
- Carol Davila University of Medicine and Pharmacy (RO)
- Carol Davila University of Medicine and Pharmacy
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2026-04-29
- Volume
- 17
- Pages
- 1815366-1815366
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC13174931
- OpenAlex
- W7159833774
- Cited by
- 0
- References
- 50
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- statins, pancreatic ductal adenocarcinoma, drug repurposing, HMGCR inhibitors, anticancer activity, tumor microenvironment, lipid rafts, protein prenylation, Ras signaling, tumor immunogenicity, mitochondrial respiration, chemosensitization, gemcitabine, 5-fluorouracil, oxaliplatin, adjuvant therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

